(Q35577700)

9 August 2017

1 reference

title

Innate immunity, local inflammation, and degenerative disease (English)

1 reference

9 August 2017

Innate Immunity, Local Inflammation, and Degenerative Disease (English)

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

29 March 2024

author name string

Patrick L. McGeer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14602998

29 March 2024

Edith G. McGeer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14602998

29 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14602998

29 March 2024

publication date

24 July 2002

1 reference

full work available at URL

9 August 2017

https://www.science.org/doi/pdf/10.1126/sageke.2002.29.re3

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Science of aging knowledge environment : SAGE KE

29 March 2024

published in

1 reference

9 August 2017

volume

2002

1 reference

9 August 2017

issue

29

1 reference

9 August 2017

page(s)

re3

1 reference

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

9 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice

29 March 2024

3

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

29 March 2024

4

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Autotoxicity and Alzheimer disease

29 March 2024

5

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease

29 March 2024

7

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease.

29 March 2024

8

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Proceedings of the National Academy of Sciences of the United States of America

29 March 2024

9

89

10016

1999

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques.

29 March 2024

11

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Up-regulated production and activation of the complement system in Alzheimer's disease brain

29 March 2024

13

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease.

29 March 2024

14

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Human heart generates complement proteins that are upregulated and activated after myocardial infarction

29 March 2024

15

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction

29 March 2024

16

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Generation of C-reactive protein and complement components in atherosclerotic plaques

29 March 2024

17

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries

29 March 2024

18

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain

29 March 2024

19

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles

29 March 2024

22

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts

29 March 2024

23

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Increased rat cardiac allograft survival by the glycosaminoglycan pentosan polysulfate

29 March 2024

24

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate.

29 March 2024

25

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Association of amyloid P component with complement proteins in neurologically diseased brain tissue

29 March 2024

26

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease.

29 March 2024

28

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?

29 March 2024

29

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment

29 March 2024

30

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

C-reactive protein and outcome after ischemic stroke

29 March 2024

31

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study

29 March 2024

32

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

29 March 2024

33

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

29 March 2024

34

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease

29 March 2024

36

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease

29 March 2024

37

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein.

29 March 2024

38

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus

29 March 2024

39

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Human astrocyte production of tumour necrosis factor-alpha, interleukin-1 beta, and interleukin-6 following exposure to lipopolysaccharide endotoxin

29 March 2024

40

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Complement and cytokine gene expression in cultured microglial derived from postmortem human brains

29 March 2024

41

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Cytokine-gene expression in measles-infected adult human glial cells

29 March 2024

42

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Alpha-2 macroglobulin is genetically associated with Alzheimer disease

29 March 2024

43

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative

29 March 2024

44

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Association of an interleukin 1 alpha polymorphism with Alzheimer's disease

29 March 2024

45

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Association of early-onset Alzheimer's disease with an interleukin-1? gene polymorphism

29 March 2024

46

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Re: Genetic effect of alpha 1-antichymotrypsin on the risk of Alzheimer disease.

29 March 2024

47

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Gene polymorphism affecting α1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk

29 March 2024

49

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer's disease and vascular dementia: a case-control study.

29 March 2024

50

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease.

29 March 2024

52

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease.

29 March 2024

53

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Polymorphisms in inflammatory genes and the risk of Alzheimer disease

29 March 2024

54

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

29 March 2024

56

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Influence of interleukin-1beta gene polymorphisms on age-at-onset of sporadic Parkinson's disease

29 March 2024

59

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Etanercept in rheumatoid arthritis

29 March 2024

60

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis

29 March 2024

61

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease

29 March 2024

63

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs.

29 March 2024

64

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex

29 March 2024

65

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity

29 March 2024

66

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus

29 March 2024

67

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia

29 March 2024

68

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases

29 March 2024

69

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Inflammation and Alzheimer's disease

29 March 2024

70

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease

29 March 2024

72

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Large-scale purification of myeloperoxidase from HL60 promyelocytic cells: characterization and comparison to human neutrophil myeloperoxidase

29 March 2024

73

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Aspirin: past, present and future

29 March 2024

74

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

29 March 2024

77

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Risk of Alzheimer's disease and duration of NSAID use.

29 March 2024

78

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

29 March 2024

81

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Randomized pilot study of nimesulide treatment in Alzheimer's disease

29 March 2024

82

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

29 March 2024

84

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Anti-inflammatory drugs and Alzheimer-type pathology in aging.

29 March 2024

85

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Clinical trial of indomethacin in Alzheimer's disease.

29 March 2024

86

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

29 March 2024

87

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs).

29 March 2024

88

1 reference

https://api.crossref.org/works/10.1126/SAGEKE.2002.29.RE3

29 March 2024

Identifiers

1 reference

9 August 2017

1 reference